Bridging Gaps for Radioligand Therapy: Policy Priorities for Scaled Implementation

A popular saying in the nuclear medicine field is that our work spans "from bench to bedside." But the path to get there isn't always clear. Even though there are constant breakthroughs in research and development, the cutting-edge treatments offered by nuclear medicine don't always make it to the patients who need it the most. Barriers within existing healthcare infrastructure, like the workforce pipeline, procedure implementation, and regulatory hurdles all contribute to gaps in patient access to radioligand therapy. But our panel of experts has solutions. In this episode of The JNM Podcast, Ken Hermann, MD, is joined by Vesna Gershan, PhD, Andrei Iagaru, MD, FACNM, FSNMMI, and Uwe Holzwarth, PhD, as they discuss how to increase patient access to nuclear medicine care. This episode is sponsored by Novartis: https://www.novartis.com/ [https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.novartis.com%2F&data=05%7C02%7Cimckenna%40snmmi.org%7C8bd9b7405ced453025d308de69766bbd%7C31a35c4d66f94a2388196f3bbcc2aa39%7C0%7C0%7C639064155471944856%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=U0f%2Bo8PGQNtbfbKO0P6KgLzEeYxnYdnH6esnklQ3vc4%3D&reserved=0]